Want to join the conversation?
$VRTX reported total CF product revenues of approx. $426MM in 2Q16 versus $155MM in 2Q15. Orkambi drug sales were $245MM. Kalydeco drug sales were up $25MM to $108MM. Operating expenses rose in 2Q16, due to increased costs related to the progression of CF pipeline and increased investments in global commercial support for the launch of Orkambi.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?